Lenalidomide with CD19 antibodies in L-MIND
Автор: ecancer
Загружено: 2017-07-06
Просмотров: 295
Описание:
Dr Maddocks speaks with ecancer at EHA 2017 about results from a single-armed phase II trial of combined immunomodulatory lenalidomide with anti-CD19 antibody MOR208 to treat refractory diffuse large B cell lymphoma (DLBCL).
She describes the monotherapy successes of both drugs leading to expectations of combined efficacy, with overall responses at a median of 3 months now being reported as 58%, with 27% achieving complete response.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке: